Articles related to NEOADJUVANT TREATMENT

The I-SPY2 trial demonstrates that novel treatment approaches can yield high pathologic complete response rates in rare histologic subtypes of high-risk breast cancer, potentially improving outcomes for these challenging cases.

In the realm of HER2-positive early breast cancer, achieving a pathological complete response (pCR) post-neoadjuvant therapy has been linked to a markedly reduced risk of recurrence, highlighting the critical role of tailored treatment strategies in improving patient outcomes.

Highlighting a paradigm shift in breast cancer treatment, the NRG Oncology/NSABP B-51/RTOG 1304 study demonstrates that certain patients with node-negative breast cancer post-neoadjuvant chemotherapy may safely omit adjuvant regional nodal irradiation, challenging conventional treatment approaches and potentially improving patient quality of life.

Discover how pre-surgery treatment with T-VEC can significantly improve long-term survival rates in advanced melanoma patients, as revealed in a recent phase 2 trial.

New data suggests that intensifying neoadjuvant therapy with abiraterone or docetaxel could significantly improve outcomes in very high-risk prostate cancer patients. Explore the full findings to consider how this could impact your treatment approach.

Explore the latest findings from the VESPER trial that suggest a promising shift in bladder cancer treatment strategy, potentially setting a new standard for neoadjuvant therapy.